1
|
Mesquita JT, Romanelli MM, de Melo Trinconi Trinconi Cm C, Guerra JM, Taniwaki NN, Uliana SRB, Reimão JQ, Tempone AG. Repurposing topical triclosan for cutaneous leishmaniasis: Preclinical efficacy in a murine Leishmania (L.) amazonensis model. Drug Dev Res 2020; 83:285-295. [PMID: 32767443 DOI: 10.1002/ddr.21725] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/19/2020] [Accepted: 07/07/2020] [Indexed: 01/07/2023]
Abstract
Leishmaniasis remains an important neglected tropical infection caused by the protozoan Leishmania and affects 12 million people in 98 countries. The treatment is limited with severe adverse effects. In the search for new therapies, the drug repositioning and combination therapy have been successfully applied to neglected diseases. The aim of the present study was to evaluate the in vitro and in vivo anti-Leishmania (Leishmania) amazonensis potential of triclosan, an approved topical antimicrobial agent used for surgical procedures. in vitro phenotypic studies of drug-treated parasites were performed to evaluate the lethal action of triclosan, accompanied by an isobolographic ex-vivo analysis with the association of triclosan and miltefosine. The results showed that triclosan has activity against L. (L.) amazonensis intracellular amastigotes, with a 50% inhibitory concentration of 16 μM. By using fluorescent probes and transmission electron microscopy, a pore-forming activity of triclosan toward the parasite plasma membrane was demonstrated, leading to depolarization of the mitochondrial membrane potential and reduction of the reactive oxygen species levels in the extracellular promastigotes. The in vitro interaction between triclosan and miltefosine in the combination therapy assay was classified as additive against intracellular amastigotes. Leishmania-infected mice were treated with topical triclosan (1% base cream for 14 consecutive days), and showed 89% reduction in the parasite burden. The obtained results contribute to the investigation of new alternatives for the treatment of cutaneous leishmaniasis and suggest that the coadministration of triclosan and miltefosine should be investigated in animal models.
Collapse
Affiliation(s)
| | | | | | | | | | - Silvia Reni Bortolin Uliana
- Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Juliana Quero Reimão
- Departamento de Morfologia e Patologia Básica, Faculdade de Medicina de Jundiaí, Jundiaí, Brazil
| | | |
Collapse
|
2
|
Romanelli MM, da Costa-Silva TA, Cunha-Junior E, Dias Ferreira D, Guerra JM, Galisteo AJ, Pinto EG, Barbosa LRS, Torres-Santos EC, Tempone AG. Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis. Front Cell Infect Microbiol 2019; 9:353. [PMID: 31737574 PMCID: PMC6828611 DOI: 10.3389/fcimb.2019.00353] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Accepted: 09/30/2019] [Indexed: 12/17/2022] Open
Abstract
Liposomes containing phosphatidylserine (PS) has been used for the delivery of drugs into the intramacrophage milieu. Leishmania (L.) infantum parasites live inside macrophages and cause a fatal and neglected viscerotropic disease, with a toxic treatment. Sertraline was studied as a free formulation (SERT) and also entrapped into phosphatidylserine liposomes (LP-SERT) against intracellular amastigotes and in a murine model of visceral leishmaniasis. LP-SERT showed a potent activity against intracellular amastigotes with an EC50 value of 2.5 μM. The in vivo efficacy of SERT demonstrated a therapeutic failure. However, when entrapped into negatively charged liposomes (−58 mV) of 125 nm, it significantly reduced the parasite burden in the mice liver by 89% at 1 mg/kg, reducing the serum levels of the cytokine IL-6 and upregulating the levels of the chemokine MCP-1. Histopathological studies demonstrated the presence of an inflammatory infiltrate with the development of granulomas in the liver, suggesting the resolution of the infection in the treated group. Delivery studies showed fluorescent-labeled LP-SERT in the liver and spleen of mice even after 48 h of administration. This study demonstrates the efficacy of PS liposomes containing sertraline in experimental VL. Considering the urgent need for VL treatments, the repurposing approach of SERT could be a promising alternative.
Collapse
Affiliation(s)
| | | | - Edezio Cunha-Junior
- Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Pavilhão Leonidas Deane, Laboratório de Bioquímica de Tripanosomatídeos, Rio de Janeiro, Brazil
| | | | | | - Andres Jimenez Galisteo
- Faculdade de Medicina, Hospital das Clínicas HCFMUSP, Universidade de São Paulo, São Paulo, Brazil
| | | | - Leandro R S Barbosa
- Instituto de Física da Universidade de São Paulo, Cidade Universitária, São Paulo, Brazil
| | - Eduardo Caio Torres-Santos
- Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Pavilhão Leonidas Deane, Laboratório de Bioquímica de Tripanosomatídeos, Rio de Janeiro, Brazil
| | | |
Collapse
|
3
|
Ferreira DD, Mesquita JT, da Costa Silva TA, Romanelli MM, da Gama Jaen Batista D, da Silva CF, da Gama ANS, Neves BJ, Melo-Filho CC, Correia Soeiro MDN, Andrade CH, Tempone AG. Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study. J Venom Anim Toxins Incl Trop Dis 2018; 24:30. [PMID: 30450114 PMCID: PMC6208092 DOI: 10.1186/s40409-018-0165-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Accepted: 10/05/2018] [Indexed: 01/07/2023] Open
Abstract
Background Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease. Methods In this work, we studied the activity of the antidepressant drug sertraline against Trypanosoma cruzi trypomastigotes and intracellular amastigotes of the Y and Tulahuen strains, and investigated its action mode using cell biology and in silico approaches. Results Sertraline demonstrated in vitro efficacy against intracellular amastigotes of both T. cruzi strains inside different host cells, including cardiomyocytes, with IC50 values between 1 to 10 μM, and activity against bloodstream trypomastigotes, with IC50 of 14 μM. Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. In silico approaches using chemogenomic target fishing, homology modeling and molecular docking suggested the enzyme isocitrate dehydrogenase 2 of T. cruzi (TcIDH2) as a potential target for sertraline. Conclusions The present study demonstrated that sertraline had a lethal effect on different forms and strains of T. cruzi, by affecting the bioenergetic metabolism of the parasite. These findings provide a starting point for future experimental assays and may contribute to the development of new compounds. Electronic supplementary material The online version of this article (10.1186/s40409-018-0165-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daiane Dias Ferreira
- Instituto Adolfo Lutz, Centre for Parasitology and Mycology, Avenida Dr. Arnaldo 351, 8° andar, sala 9, CEP, São Paulo, SP 01246-000 Brazil
| | - Juliana Tonini Mesquita
- Instituto Adolfo Lutz, Centre for Parasitology and Mycology, Avenida Dr. Arnaldo 351, 8° andar, sala 9, CEP, São Paulo, SP 01246-000 Brazil
| | - Thais Alves da Costa Silva
- Instituto Adolfo Lutz, Centre for Parasitology and Mycology, Avenida Dr. Arnaldo 351, 8° andar, sala 9, CEP, São Paulo, SP 01246-000 Brazil
| | - Maiara Maria Romanelli
- Instituto Adolfo Lutz, Centre for Parasitology and Mycology, Avenida Dr. Arnaldo 351, 8° andar, sala 9, CEP, São Paulo, SP 01246-000 Brazil
| | - Denise da Gama Jaen Batista
- 2Fundação Oswaldo Cruz, Laboratório de Biologia Celular do Instituto Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, CEP, Rio de Janeiro, RJ 21040-360 Brazil
| | - Cristiane França da Silva
- 2Fundação Oswaldo Cruz, Laboratório de Biologia Celular do Instituto Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, CEP, Rio de Janeiro, RJ 21040-360 Brazil
| | - Aline Nefertiti Silva da Gama
- 2Fundação Oswaldo Cruz, Laboratório de Biologia Celular do Instituto Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, CEP, Rio de Janeiro, RJ 21040-360 Brazil
| | - Bruno Junior Neves
- 3Faculdade de Farmácia, Universidade Federal de Goiás, Rua 240 Setor Leste Universitário, Goiânia, GO 74605170 Brazil
| | - Cleber Camilo Melo-Filho
- 3Faculdade de Farmácia, Universidade Federal de Goiás, Rua 240 Setor Leste Universitário, Goiânia, GO 74605170 Brazil
| | - Maria de Nazare Correia Soeiro
- 2Fundação Oswaldo Cruz, Laboratório de Biologia Celular do Instituto Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, CEP, Rio de Janeiro, RJ 21040-360 Brazil
| | - Carolina Horta Andrade
- 3Faculdade de Farmácia, Universidade Federal de Goiás, Rua 240 Setor Leste Universitário, Goiânia, GO 74605170 Brazil
| | - Andre Gustavo Tempone
- Instituto Adolfo Lutz, Centre for Parasitology and Mycology, Avenida Dr. Arnaldo 351, 8° andar, sala 9, CEP, São Paulo, SP 01246-000 Brazil
| |
Collapse
|